Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

National, Multicenter, Open-Label and Prospective Study Assessment of Efficacy and Safety in Stage 1 and 2 Essential Hypertension With Olmesartan Medoxomil Based Treatment Algorithm From Monotherapy to Association With Hydrochlorothiazide and Amlodipine Besylate

NCT00890591 is registered in ClinicalTrials.gov with Daiichi Sankyo as lead sponsor.

NCT NCT00890591
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00890591 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
National, Multicenter, Open-Label and Prospective Study Assessment of Efficacy and Safety in Stage 1 and 2 Essential Hypertension With Olmesartan Medoxomil Based Treatment Algorithm From Monotherapy to Association With Hydrochlorothiazide and Amlodipine Besylate
Lead sponsor
Daiichi Sankyo
Phase
Phase 4
Overall status
Completed
Start date
August 31, 2006
Completion date
August 31, 2007
Enrollment
144 (actual)
Sites
Not reported

Conditions

As the registry lists them; a condition with its own page is linked.

essential hypertension